Comments Regarding Quantitative Labeling of Sodium, Potassium, and Phosphorus for OTC and Prescription Drug Products Share page: Docket Number: FDA-2021-D-0528 Download Document Issues: OTC Medicines Other Issues Labeling Quality Related Posts Press Releases and Statements CHPA Applauds White House Executive Order Prioritizing Lower Drug Costs and Access to Self-Care Apr 17, 2025 Press Releases and Statements CHPA Responds to Section 232 Investigation on Pharmaceuticals Apr 15, 2025 Press Releases and Statements CHPA Commends Lawmakers for Urging FDA to Protect the Rx-OTC-Switch Pathway Apr 11, 2025